News Release

Nanocomposite developed for NIR-II light-boosted photodynamic/chemodynamic therapy

Peer-Reviewed Publication

Hefei Institutes of Physical Science, Chinese Academy of Sciences

Nanocomposite Developed for NIR-II Light-Boosted Photodynamic/Chemodynamic Therapy

image: The research results were published in Langmuir and recommended as Journal's front cover. view more 

Credit: Shereen M. Elsherbiny

Recently, a research team led by Prof. HUANG Qing at the Institute of Intelligent Machines, Hefei Institutes of Physical Science (HFIPS) provided a new nanocomposite based on Bi2MoO6/MoS2/AuNRs for near-infrared (NIR)-II light-boosted photodynamic/chemodynamic therapy.

The results have been published in Langmuir and recommended as Journal's front cover.

Bi2MoO6 (BMO) nanoparticles (NPs) have been extensively used in photocatalytic applications. Also, utilized as a photosensitizer in photodynamic therapy. However, their UV absorption property hinders their clinical application.

In this research, scientists designed a new nanocomposite named Bi2MoO6/MoS2/AuNRs (BMO-MSA) by modified Bi2MoO6 (BMO) by MoS2/AuNRs (MSA) hybrid. They found that the resulting nanocomposite can absorb light in the NIR-II range. The outcomes of the research revealed that after exposured to light with wavelength 1064 nm, the BMO-MSA produced singlet oxygen (1O2) with quantum yield (QY) = 0.32 which confirmed its photodynamic therapy (PDT) ability. Moreover, it has POD-like activity, which enhances the chemodynamic therapy (CDT) effect.

To investigate the in vivo PDT efficiency of BMO-MSA, the researcher studied the germline apoptosis based on their previously C. elegans-established PDT model. The findings demonstrated that PDT caused germline apoptosis in the worm through the cep-1 pathway due to DNA damage. This finding was further supported by the utilization of a variety of mutants that had a lack of function related to DNA damage genes.

This work has not only provided a novel PDT agent which may be used for PDT in the NIR-II region but also introduced a new approach to therapy taking advantage of both PDT and CDT effects, according to the team.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.